4 Takeaways As AbbVie Crushes 'Patent Thicket' Litigation
Law360 (June 12, 2020, 9:46 PM EDT) -- AbbVie's rapid and resounding defeat of high-profile antitrust litigation targeting a "patent thicket" guarding Humira, the world's best-selling drug, will help Big Pharma plant dense new jungles of intellectual property to block biosimilar makers that are already struggling to penetrate the lucrative biologics sector.
AbbVie's injectable biologic Humira has generated enormous sales as a treatment for rheumatoid arthritis, plaque psoriasis and other conditions. (JB Reed/Bloomberg via Getty Images) The June 8 triumph by Illinois-based AbbVie Inc. ended a consolidated set of proposed class actions filed last year in Illinois federal court. At issue was AbbVie's enormous appetite for Humira patents and its alleged "pay-for-delay"...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!